These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22680253)

  • 21. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
    J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine in the treatment of elderly people with major depressive disorder.
    Del Casale A; Girardi P; Brugnoli R; Sani G; Di Pietro S; Brugnoli C; Caccia F; Angeletti G; Serata D; Rapinesi C; Tatarelli R; Kotzalidis GD
    Riv Psichiatr; 2012; 47(6):479-88. PubMed ID: 23160108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial.
    Englisch S; Knopf U; Scharnholz B; Kuwilsky A; Deuschle M; Zink M
    J Psychopharmacol; 2009 Nov; 23(8):875-82. PubMed ID: 18583440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment.
    Wang Y; Jia Y; Chen X; Ling X; Liu S; Xu G; Huang L
    J Psychopharmacol; 2012 Nov; 26(11):1463-70. PubMed ID: 22706518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder.
    Walderhaug E; Kasserman S; Aikins D; Vojvoda D; Nishimura C; Neumeister A
    Pharmacopsychiatry; 2010 Mar; 43(2):45-9. PubMed ID: 20108200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duloxetine Eli Lilly.
    Anttila S; Leinonen E
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1217-21. PubMed ID: 12211418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
    McIntyre RS; Konarski JZ
    Expert Opin Pharmacother; 2005 May; 6(5):707-13. PubMed ID: 15934897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuation treatment of major depressive disorder: is there a case for duloxetine?
    Norman TR; Olver JS
    Drug Des Devel Ther; 2010 Feb; 4():19-31. PubMed ID: 20368904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
    Augendre-Ferrante B; Picard H; Evans D; Arkoub H; Pamulapati S; Perrot S; Valensi P; Rouillon F
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):1-7. PubMed ID: 24161159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.
    Wohlreich MM; Sullivan MD; Mallinckrodt CH; Chappell AS; Oakes TM; Watkin JG; Raskin J
    Psychosomatics; 2009; 50(4):402-12. PubMed ID: 19687181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.